stx-478
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 17, 2023 (NCT05768139)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c([C@@H](NC(=O)Nc2cnc(N)nc2)C(F)(F)F)oc2c(F)cc(F)cc12- Mol. weight
- 401.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5421037 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07174336 | Phase 3 | Oct 27, 2025 | Eli Lilly, Pfizer |
| NCT07247357 | Phase 1 | Oct 24, 2025 | Eli Lilly |
| NCT06991179 | Phase 1 | May 20, 2025 | Eli Lilly |
| NCT06901336 | Phase 1 | Mar 20, 2025 | Eli Lilly |
| NCT05768139 | Phase 1/Phase 2 (Phase 2) | Apr 17, 2023 | Scorpion Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 2 | 2025 |
| Pfizer | For profit | 1 | 0 | 1 | 2025 |
| Scorpion Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1